Paget's disease is a progressive focal bone condition which can result in pain, low quality of life, deformity and other complications. Disease progression can be halted with potent bisphosphonates, resulting in improvement in both quality of life and pain, and normalisation of scintigraphy, plain radiographs and bone histology. Zoledronate has transformed the treatment of Paget's disease, producing sustained remissions in almost all patients. Thus, it is now possible to normalise bone cell activity and prevent disease progression at low cost, with one or two intravenous injections of zoledronate, greatly reducing follow-up costs. Patients with Paget's disease who are symptomatic or at risk of complications should have the opportunity to reap these therapeutic benefits. Potent bisphosphonates are highly effective in halting disease progression in Paget's disease, but guidelines disagree about treatment indications. The efficacy, safety and low cost of zoledronate recommend its use in any patient who is symptomatic or judged to be at risk of complications from Paget's disease.

中文翻译：

---

佩吉特氏骨病的管理。

佩吉特氏病是一种进行性局灶性骨病，可能导致疼痛，生活质量低下，畸形和其他并发症。有效的双膦酸盐可阻止疾病进展，从而改善生活质量和疼痛，并使闪烁显像，平片和骨组织学正常化。唑来膦酸盐改变了Paget病的治疗方法，几乎​​使所有患者的病情持续缓解。因此，现在有可能通过一次或两次静脉注射唑来膦酸盐来低成本地使骨细胞活性正常化并预防疾病进展，从而大大降低了后续费用。有症状或有并发症风险的Paget病患者应有机会获得这些治疗益处。有力的双膦酸盐在阻止佩吉特氏病的疾病进展方面非常有效，但指南对治疗适应症持不同意见。唑来膦酸盐的疗效，安全性和低成本建议将其用于有症状或被认为有患Paget病并发症风险的任何患者。